Merz Pharmaceuticals offers $22 a share for Obagi (OMPI) and trumps Valeant's (VRX) bid of...


Merz Pharmaceuticals offers $22 a share for Obagi (OMPI) and trumps Valeant's (VRX) bid of $19.75 , which valued Obagi at $360M. Merz says it has the money to pay for the deal and doesn't need to carry out further due diligence, as it was already in talks to buy Obagi when the Valeant deal was announced. Obagi surges 15.2% to $22.70.

From other sites
Comments (2)
  • raktim81
    , contributor
    Comments (5) | Send Message
     
    gah! sold it at 19.73
    2 Apr 2013, 09:34 AM Reply Like
  • Smot
    , contributor
    Comments (8) | Send Message
     
    Me too- Sold at 19.73
    2 Apr 2013, 04:44 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs